Bottom line
How much do IBB and PBE overlap?
36% of their top holdings overlap by weight. 12 securities appear in both funds' top 25, making up 44.4% of IBB's assets and 46.8% of PBE's. They share a meaningful core but differ in the rest of the portfolio.
IBB holds far more positions (254 vs 33), so it is broader beyond the top names.
Updated Nov 22, 2026
Overlap at a glance
Holdings IBB and PBE have in common
| Holding | % of IBB | % of PBE | Overlap |
|---|---|---|---|
| Vertex Pharmaceuticals, Inc. | 7.66% | 4.99% | 4.99% |
| Gilead Sciences, Inc. | 7.52% | 4.43% | 4.43% |
| Amgen, Inc. | 7.50% | 5.22% | 5.22% |
| Regeneron Pharmaceuticals, Inc. | 5.70% | 5.47% | 5.47% |
| Alnylam Pharmaceuticals, Inc. | 5.68% | 3.17% | 3.17% |
| Biogen, Inc. | 2.03% | 4.79% | 2.03% |
| United Therapeutics Corp. | 1.82% | 4.08% | 1.82% |
| Incyte Corp. | 1.62% | 3.06% | 1.62% |
| Illumina, Inc. | 1.41% | 3.51% | 1.41% |
| Neurocrine Biosciences, Inc. | 1.34% | 2.66% | 1.34% |
| Exelixis, Inc. | 1.07% | 2.64% | 1.07% |
| BioMarin Pharmaceutical, Inc. | 1.02% | 2.82% | 1.02% |
Source: SEC Form N-PORT (periods Sep 30, 2025 / Jul 31, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in IBB
- BlackRock Funds III — 13.18%
- IQVIA Holdings, Inc. — 3.18%
- Argenx SE — 3.15%
- Insmed, Inc. — 2.95%
- Mettler-Toledo International, Inc. — 2.49%
- Natera, Inc. — 2.11%
- BeOne Medicines Ltd. — 2.11%
- Waters Corp. — 1.77%
- Genmab A/S — 1.38%
- Medpace Holdings, Inc. — 1.16%
- Ionis Pharmaceuticals, Inc. — 1.03%
- Madrigal Pharmaceuticals, Inc. — 0.92%
- Moderna, Inc. — 0.88%
Only in PBE
- Invesco Private Prime Fund — 12.89%
- CareDx, Inc. — 5.04%
- Invesco Private Government Fund — 4.97%
- Royalty Pharma PLC — 4.94%
- Bio-Techne Corp. — 3.73%
- Protagonist Therapeutics, Inc. — 3.40%
- Vericel Corp. — 3.27%
- Repligen Corp. — 3.04%
- Acadia Pharmaceuticals Inc. — 3.02%
- Halozyme Therapeutics, Inc. — 2.98%
- Qiagen N.V. — 2.89%
- BioCryst Pharmaceuticals, Inc. — 2.63%
- Veracyte, Inc. — 2.60%
Asset mix
| Asset type | IBB | PBE |
|---|---|---|
| Stocks | 99.8% | 100.1% |
| Cash & short-term funds | 13.4% | 17.9% |
Source: SEC Form N-PORT (periods Sep 30, 2025 / Jul 31, 2026)
Country mix
| Country | IBB | PBE |
|---|---|---|
| US | 98.6% | 108.6% |
| GB | 1.0% | 4.9% |
| NL | 4.3% | 2.9% |
| CH | 2.7% | — |
| DK | 2.2% | — |
| KY | 0.9% | 1.6% |
| DE | 0.7% | — |
| BM | 0.7% | — |
Source: SEC Form N-PORT (periods Sep 30, 2025 / Jul 31, 2026)
Check another pair
FAQ
How much do IBB and PBE overlap?
What stocks do IBB and PBE have in common?
Should I own both IBB and PBE?
Which holds more stocks, IBB or PBE?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.